BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ICON Acquires Assets of Qualia Clinical Services


4/28/2009 2:48:18 PM

Dublin, Ireland, April 28th, 2009. ICON plc, NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has acquired a 33,000 square foot Phase I facility with a capacity of up to 100 beds in Omaha, Nebraska, having acquired the assets of the former Qualia Clinical Services, Inc.

ICON has also announced the appointment of Dr. Gary Curtis as Senior VP, Global Clinical Pharmacology. Dr Curtis will integrate the Omaha facility with ICON’s existing Phase I units and will be supported by key clinical operational staff from Qualia who have been rehired by ICON.

“This latest acquisition supports our strategy of expanding our Phase I capabilities in the US and brings our total bed capacity there to approximately 225 beds,” commented Dr. Thomas Frey, President, ICON Development Solutions. “We have acquired an excellent facility and we have put in place an experienced team who will ensure the delivery of quality clinical pharmacology services to clients.”

Dr. Curtis comes to ICON after spending nearly 20 years with MDS Pharma Services where he was responsible for operational execution, strategic growth, and integration of MDS’ global early phase business units. Dr. Curtis’ extensive expertise in early phase clinical operations on a global scale will complement ICON’s existing scientific clinical pharmacology leadership.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,100 employees, operating from 71 locations in 38 countries. Further information is available at www.iconplc.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES